Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
7 May 2019Americas

GSK ordered to pay Vectura $89.7m in patent damages

British drugmaker  Vectura has succeeded in its  patent litigation against fellow UK pharmaceutical company  GlaxoSmithKline (GSK) over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Vectura wins additional $10m patent damages against GSK
16 September 2019   A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Big Pharma
GSK awarded Arrow declaration in patent dispute with Vectura
17 December 2018   The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.
Americas
Vectura sues GSK for patent infringement
29 July 2016   Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Big Pharma
Vectura wins additional $10m patent damages against GSK
16 September 2019   A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Big Pharma
GSK awarded Arrow declaration in patent dispute with Vectura
17 December 2018   The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.
Americas
Vectura sues GSK for patent infringement
29 July 2016   Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.

More on this story

Big Pharma
Vectura wins additional $10m patent damages against GSK
16 September 2019   A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Big Pharma
GSK awarded Arrow declaration in patent dispute with Vectura
17 December 2018   The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.
Americas
Vectura sues GSK for patent infringement
29 July 2016   Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory